Original paper

Elevated cystatin C: is it a reflection for kidney or liver impairment in hepatic children?

Behairy El-Sayed1, Hanaa El-Araby1, Nermin Adawy1, Mona Hassona2, Naglaa El-Nady1, Haidy Zakaria4, Mohammed Khedr1

1Pediatric Hepatology Department, National Liver Institute, Menofiya University, Egypt
2Clinical Pathology Department, National Liver Institute, Menofiya University, Egypt
3Pediatric Department, Meet-Ghamr Central Hospital, Ministry of Health, Dakahlyia, Egypt
4Pediatric Department, Quesna Central Hospital, Ministry of Health, Menofiya, Egypt

Abstract

Aim of the study: To assess if elevated serum cystatin C (Cyst-C) is an indicator for renal or hepatic dysfunction in presence of liver fibrosis.

Material and methods: Data of 50 children with chronic liver diseases (CLDs), out of which 25 were without renal impairment, and 25 with renal impairment were analyzed. Twenty healthy children served as a healthy control group. Routine investigations, creatinine clearance, hepatitis viral markers, abdominal ultrasonography, and liver biopsy were performed for patients with CLDs. Measurement of serum Cyst-C concentration by particle induced immunonephelometry were completed for both patients and control group.

Results: Results showed that serum Cyst-C is not correlated with the degree of hepatic impairment ($p > 0.05$). Cyst-C levels were significantly higher in patients with renal impairment ($3.66 \pm 0.85$) than those without ($0.71 \pm 0.12$), and healthy control group ($0.63 \pm 0.85$). Cystatin-C showed significant elevation in patients with severe fibrosis with renal impairment ($3.66 \pm 0.85$) than those without ($0.76 \pm 0.04$) ($p < 0.0001$). Cyst-C at cutoff levels of 1.65 mg/l showed 100% accuracy in discrimination between those with and those without renal impairment. Cyst-C > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. Cyst-C > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%.

Conclusions: Serum Cyst-C is a promising marker to estimate renal impairment in children with CLDs. Further studies are needed to estimate the accuracy of serum Cyst-C for early detection of renal impairment and close monitoring of the hepatic children.

Key words: cystatin C, chronic liver disease, renal impairment.

Address for correspondence

Dr. Haidy Zakaria, Quesna Central Hospital, Quesna, Menofiya, Egypt, 20048 Quesna, Egypt, phone: +2 01005768306, e-mail: drhaydi2000@gmail.com

Introduction

Chronic liver diseases (CLDs) are an important health issue since severe hepatic dysfunction could lead to persistent inflammation, necrosis, liver cirrhosis, and even hepatocellular carcinoma [1]. Hepatorenal syndrome (HRS) is a reversible functional renal impairment that occurs in patients with advanced liver cirrhosis or those with fulminant hepatic failure. It is characterized by marked reduction in glomerular filtration rate (GFR) and renal plasma flow (RPF) in the absence of other causes of renal failure; tubular function is preserved with the absence of proteinuria or histological changes in the kidney [2].

Demonstration of renal dysfunction by traditional methods has many difficulties. Serum creatinine (Cr) or calculated Cr clearance are the most convenient estimates of GFR, requiring only a single blood sample. However, serum Cr measurements in cirrhosis are affected by different factors such as loss of muscle mass, reduced dietary protein intake, sex, and ethnic origin as well as by interference with the standard Jaffe colo-
rimetric method of Cr determination by bilirubin and other compounds, which accumulate in liver failure. On the other hand, Cr is an imperfect filtration marker, because it is secreted by the tubular cells into the tubular lumen, especially if renal function is impaired. When the GFR is low, the serum Cr and Cr clearance overestimate the true GFR. Some drugs (such as cimetidine or trimethoprim) have the effect of reducing tubular secretion of Cr. Similarly, urea is synthesized by the liver and may be reduced as a consequence of hepatic insufficiency [3].

Creatinine clearance needs 24-hours urine collection, therefore it’s unreliable especially in out-patients, as the collection may be incomplete. This results in an underestimation of renal function [4]. Inulin clearance cost and technical difficulties preclude its routine use [3]. β₂ microglobulin is affected by presence of infections or malignancies. Chromium⁵¹ labeled ethylenediaminetetraacetic acid (⁵¹Cr-EDTA) is costly, invasive, time consuming, and stressful for children and parents [5].

Cystatin C (Cyst-C), a low molecular weight protein produced at a constant rate by all nucleated cells, freely filtered across the glomerular membrane and neither secreted or absorbed, and completely catabolized in the proximal tubule, independent of muscle mass, sex and age [3]. Plasma cyst-C is a new marker of GFR [6], which provides accurate data for calculating GFR independent of the drug doses [7].

The value of serum Cyst-C as a marker for liver fibrosis and renal dysfunction in children with CLDs will be evaluated in our study.

Material and methods

Data of fifty children with CLDs with different etiologies (Table 1) from the Pediatric Hepatology Department, National Liver Institute, Menofia University, between May 2011 and May 2015 were analyzed. Twenty-five of them were without renal impairment (group 1), and 25 children with renal impairment (group 2), which was evaluated on the base of blood urea, serum Cr, and Cr clearance. Twenty healthy children of matched age and sex serves as a healthy control group (group 3). All children were provided with a written informed consent that was signed by the parents of each child in order to participate in the study, and for collection and storage of serum. The study was approved by the Research Ethics Committee of the National Liver Institute, Menofia University, and conforms to the 1975 Declaration of Helsinki.

Diagnosis of CLDs were based on clinical, biochemical, serological, and histopathological investigations. All groups included in this study were investigated on the base of full medical history and through clinical examinations. Complete blood count (CBC), liver function tests (LFTs), complete urinalysis, blood urea, serum Cr, and Cr clearance, hepatitis markers, especially hepatitis B (HB) surface antigen, anti-HB core antibody, and hepatitis C virus (HCV) antibody were performed for all patients. Measurement of serum Cyst-C concentration by particle induced immunonephelometry were performed for all patients and the control group. Abdominal ultrasonographic examination was completed to define the status of the liver, spleen, kidney, and other abdominal findings. Ultrasound-guided liver biopsy specimens were performed for all the patients. Serum samples were obtained, and renal functions were assessed by serum Cr, calculated GFR (CGFR) and serum Cyst-C measurement. Serum Cr was measured by Jaffe reaction using Bayer Dax 48 and expressed in micromole per liter. CGFR was obtained by applying the Schwartz formula:

\[
\text{CGFR} = \frac{\text{Height (cm)} \times 0.413}{\text{Cr (mm/l)}}
\]

| Group 1 (n = 25) % Cystatin-C level | Group 2 (n = 25) % Cystatin-C level |
|-----------------------------------|-----------------------------------|
| Cholestasis 36 0.70 ± 0.14 Viral hepatitis (B & C) 52 3.43 ± 0.8 |
| Wilson's disease 16 0.79 ± 0.01 Budd-Chiari syndrome 20 4.05 ± 1.4 |
| Viral hepatitis 12 0.75 ± 0.04 Congenital hepatic fibrosis 16 3.98 ± 0.14 |
| Naïve autoimmune hepatitis 12 0.63 ± 0.34 Naïve autoimmune hepatitis 12 3.55 ± 0.1 |
| Metabolic disease 8 0.67 ± 0.14 |
| Congenital hepatic fibrosis 8 0.72 ± 0.13 |
| Malignancy (hepatoblastoma) 4 0.71 ± 0.15 |
| Budd-Chiari syndrome 4 0.71 ± 0.17 |

\( p \)-value 0.789 0.497
Serum Cyst-C was measured with N Latex Cyst-C kit on the Dad Behring Nephelometer BN2, using the particle enhanced nephelometric immunoassay (PENIA) methods. Results are expressed in mg/l.

Impaired GFR was defined as: GFR > 80 ml/min/1.73 m² [8].

Statistical analysis was performed by SPSS (Statistical Package for Social Science) program version 13 for Windows. Correlation between quantitative variables were assessed with the Spearman correlation coefficient (r). Comparisons of quantitative data between each 2 groups were done by Mann-Whitney U-test. χ² test was used to compare the qualitative data. The diagnostic validity of Cyst-C to detect reduced GFR was evaluated by receiver operative characteristic curve (ROC) analysis. SPSS was used for calculation of the area under the ROC curve, and the sensitivity/specificity data at certain cutoffs.

Results

In total, 50 children with CLDs were enrolled in the study; 25 of them without renal impairment (group 1) and 25 with renal impairment (group 2). Twenty healthy children (group 3) represented healthy control group. Group 1, group 2, and group 3 mean age were 8.9 ± 2.8, 10.2 ± 3.1, and 9.6 ± 4.6 years, respectively (p = 0.183). Males represented 64%, 64%, and 60% in group 1, group 2, and group 3, respectively (p = 0.916). On comparing, the levels of cystatin-C between different etiologies in each group were found of no significant difference (Table 1).

No statistical significant difference between group 1 and 2, with regards to CBC parameters and LFTs were found. Urea, Cr levels, and Cyst-C levels were significantly higher in group 2 than in group 1 and 3. Cr clearance was significantly impaired in group 2, while no significant difference was found between group 1 and 3 (Table 2). Cyst-C, at a cutoff level of 1.65 mg/l had sensitivity, specificity, and positive predictive value (PPV). Negative predictive value (NPV) and accuracy of 100% in discrimination between those with renal impairment and those without (Fig. 1) were found. Cyst-C > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. Cyst-C > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%. Significant correlation between Cyst-C and AST, ALT, and GGT was found in group 1, while we did not found similar results in group 2 (Table 3). Cyst-C was not correlated with the true function of the liver (albumin and prothrombin) in any of both groups (Table 3).

On assessing the mean level of cystatin-C in different grades of fibrosis, we found significant elevation in cystatin-C level in kidney impaired patients with severe fibrosis (3.66 ± 0.85) than patients with severe fibrosis but with preserved kidney function (0.76 ±

### Table 2. Disease duration and laboratory parameters in all studied groups

| Parameters       | Group 1 (n = 25) | Group 2 (n = 25) | Group 3 (n = 20) | P1       | P2       | P3       |
|------------------|------------------|------------------|------------------|----------|----------|----------|
| Disease duration (years) | 3.8 ± 1.9        | 5.5 ± 2.7        | -                 | 0.027    |          |          |
| Hb (gm/dl)       | 10.25 ± 1.8      | 9.29 ± 1.1       | 11.91 ± 0.87     | 0.077    | < 0.0001 | < 0.0001 |
| WBC × 10⁹/ml     | 10.66 ± 9.2      | 11.68 ± 6.9      | 7.68 ± 2.04      | 0.177    | 0.472    | 0.011    |
| Platelets × 10⁹/ml | 178.8 ± 137.7    | 133.84 ± 100.4   | 243.2 ± 73.2     | 0.268    | 0.018    | < 0.0001 |
| TB (mg/dl)       | 10.6 ± 14.2      | 8.60 ± 10.5      | 0.86 ± 0.17      | 0.961    | 0.004    | < 0.0001 |
| DB (mg/dl)       | 6.18 ± 8.1       | 6.22 ± 8.2       | 0.15 ± 0.39      | 0.846    | < 0.0001 | < 0.0001 |
| ALT (IU/l)       | 127.30 ± 106     | 89.72 ± 65.4     | 23.2 ± 7.1       | 0.177    | < 0.0001 | < 0.0001 |
| AST (IU/l)       | 183.24 ± 204     | 111.64 ± 67.4    | 20.2 ± 6.6       | 0.574    | < 0.0001 | < 0.0001 |
| GGT (IU/l)       | 100 ± 101.9      | 107.6 ± 102.4    | 25.2 ± 7.58      | 0.938    | < 0.0001 | < 0.0001 |
| TP (gm/dl)       | 6.06 ± 0.79      | 6.17 ± 1.1       | 7.06 ± 0.27      | 0.892    | < 0.0001 | 0.011    |
| Alb (gm/dl)      | 2.08 ± 0.87      | 2.65 ± 1.05      | 4.18 ± 0.32      | 0.214    | < 0.0001 | < 0.0001 |
| PC %             | 52.6 ± 26.7      | 52.1 ± 19.2      | 94.4 ± 4.35      | 0.648    | < 0.0001 | < 0.0001 |
| UREA (mg/dl)     | 32.83 ± 27.9     | 192.44 ± 74.7    | 26.7 ± 7.62      | < 0.0001 | 0.314    | < 0.0001 |
| Cr (mg/dl)       | 0.47 ± 0.24      | 3.61 ± 1.5       | 0.66 ± 0.27      | < 0.0001 | 0.127    | < 0.0001 |
| Cr clearance (ml/min) | 121.8 ± 11.1    | 23.96 ± 8.2      | 124.8 ± 13.7     | < 0.0001 | 0.464    | < 0.0001 |
| Cyst-C (mg/l)    | 0.71 ± 0.12      | 3.66 ± 0.85      | 0.63 ± 0.85      | < 0.0001 | 0.08     | < 0.0001 |

P1 – probability of significance between group 1 and group 2; P2 – probability of significance between group 1 and group 3; P3 – probability of significance between group 2 and group 3
and those with moderate (0.63 ± 0.12) and mild fibrosis (0.73 ± 0.14) ($p < 0.0001$).

**Discussions**

Attempts have been made to use non-invasive techniques for assessment of the degree of liver fibrosis and renal impairment in hepatic children.

The current study showed that serum Cyst-C levels is affected by the degree of kidney impairment (group 2). Serum Cyst-C levels were closely correlated with the levels of urea, Cr, and Cr-GFR. In agreement with that of Park et al., an increased serum Cyst-C levels were found to be related to decreased renal function [9]. Moreover, several reports have suggested that Cyst-C is more sensitive than Cr in detecting reduced renal function, and its levels are a good marker for predicting HRS and survival in patients with cirrhotic ascites and normal Cr levels [10]. Gerbes et al. reported that serum Cyst-C proved to be a valuable tool for early diagnosis of moderately impaired renal function in adult patients with cirrhosis [11].

The absence of correlation between serum Cyst-C and true functions of the liver (albumin and prothrombin) is associated with significant elevation of Cyst-C level in patients with severe fibrosis with renal impairment than in those without renal impairment. The nearer the levels of Cyst-C in control group and in patients without renal impairment, and absence of association between Cyst-C and the etiology of liver disease, reflects that the variations of Cyst-C levels occurred most likely according to the severity of renal impairment.

**Fig. 1.** ROC curve showing performance of Cyst-C in discrimination between different grades of renal impairment.

| GFR < 80 | GFR < 40 | GFR < 20 |
|----------|----------|----------|
| AUROC    | 1        | 0.996    | 0.868    |
| $p$-value| < 0.0001 | < 0.0001 | < 0.0001 |
| Cutoff   | > 1.65   | > 2.34   | > 2.73   |
| Sensitivity | 100%  | 100%    | 100%    |
| Specificity | 100%  | 97.8%   | 76.7%   |
| PPV      | 100%     | 100%    | 80%     |
| NPV      | 100%     | 100%    | 95.8%   |
| Accuracy | 100%     | 99%     | 81.5%   |

AUROC – area under the receiver operative characteristic curve, PPV – positive predictive value, NPV – negative predictive value.
impairment, rather than severity of the hepatic condition. This was in accordance with a study done by Buyukberber et al., which may add to the accuracy of Cyst-C in detecting kidney function [12]. In agreement with that, Orlando et al. reported that plasma Cyst-C is a more accurate GFR marker in cirrhotic adult patients than plasma Cr and Cr-GFR [3].

We had calculated a Cyst-C cutoff point, validity in detecting cases of CLDs with renal impairment at 1.65 mg/l with 100% sensitivity and 100% specificity. Cyst-C > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. Cyst-C > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%. Similar results were reported by Samyn et al.; they calculated a Cyst-C cutoff point at 1.06 mg/l with 91% sensitivity and 81% specificity [5]. Also, Kim et al. presented that the cutoff value of 1.1 mg/l could be an adequate reference levels for detecting early renal dysfunction in these patients [13]. Omar et al. found that serum CysC and CysC-based formulae were not only the best measures that reflected the actual renal performance in cirrhotic patients, but also the most accurate in detecting early stages of renal impairment in these patients [14].

Conclusions

Serum Cyst-C is a promising marker to estimate renal impairment in children with CLDs. Further studies are needed to estimate the accuracy of serum Cyst-C for early detection of renal impairment and close monitoring of the hepatic children.

Acknowledgements

We thank the patients and investigators who participated in the study, especially the investigators who responded to our inquiries. We also thank our colleagues, Pediatric Hepatology Department, National Liver Institute, Menofia University.

Disclosure

Authors report no conflict of interest.

References

1. Chu SC, Wang CP, Chang YH, et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 2004; 341: 133-138.
2. Wadie HM, Mai ML, Ahsan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066-1079.
3. Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48: 850-858.
4. Sidlova K, Slamenik M, Juklova J, et al. Importance of determination of cystatin C serum levels in pediatric patients with kidney diseases. Cas Lek Cesk 2001; 140: 147-149.
5. Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transplantation 2005; 11: 344-349.
6. Le Bricon T, Leblanc I, Benlahel M, et al. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med 2005; 43: 953-957.
7. Foster J, Reisman W, Lepage N, et al. Influence of commonly used drugs on the accuracy of cystatin C-derived glomerular filtration rate. Pediatr Nephrol 2006; 21: 235-238.
8. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637.
9. Park JS, Kim GH, Kang CM, et al. Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules. Korean J Intern Med 2010; 25: 77-81.
10. Cimerman N, Brugaljan PM, Krasovec M, et al. Serum cystatin C, a potent inhibitor of cytotoxic proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000; 300: 83-85.
11. Gerbes A, Gulberg V, Bilzer M, et al. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-110.
12. Buyukberber M, Koruk I, Cýkman O, et al. Serum cystatin C measurement in differential diagnosis of intra and extrahepatic cholestatic diseases. Ann Hepatol 2010; 9: 58-62.
13. Kim DJ, Kang HS, Choi HS, et al. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol 2011; 17: 130-138.
14. Omar M, Abdel-Razek W, Abo-Raia G, et al. Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis. Int J Hepatol 2015; 2015: 309042.

Table 3. Correlation between Cyst-C in CLDs with and without renal impairment according to age, disease duration, and liver function

| Parameter            | Group 1 (n = 25) | Group 2 (n = 25) |
|----------------------|-----------------|-----------------|
|                      | r                | p-value         | r                | p-value         |
| Age (year)           | 0.184            | <0.069          | 0.742            |
| Disease duration (year) | 0.163            | 0.178           | 0.396            |
| T. bilirubin (mg/dl)  | 0.151            | 0.246           | 0.237            |
| D. bilirubin (mg/dl)  | 0.150            | 0.307           | 0.136            |
| ALT (IU/l)           | 0.441            | 0.021           | 0.920            |
| AST (IU/l)           | 0.667            | <0.0001         | 0.687            |
| GGT (IU/l)           | -0.462           | -0.140          | 0.504            |
| TP (gm/dl)           | -0.094           | 0.210           | 0.313            |
| Alb (gm/dl)          | 0.035            | 0.082           | 0.698            |
| PC (%)               | 0.201            | 0.048           | 0.821            |
| Cr (mg/dl)           | 0.433            | 0.855           | <0.0001          |
| Cr clearance (ml/min)| -0.951           | <0.0001         | -0.977           | <0.0001         |